CALCIFIC AORTIC STENOSIS AND OSTEOPOROSIS: GENERAL MECHANISMS AND PERSPECTIVES OF PHARMACOLOGICAL CORRECTION
https://doi.org/10.17650/1818-8338-2011-2-86-93
Abstract
The article discusses many common clinical and laboratory features of calcific aortic stenosis (CAS) and osteoporosis in patients of advanced age. After evaluation of bone mineral density, risk factors of fractures and falls, in conjunction with bone turnover markers, 2 distinct types of osteoporosis in CAS patients were described. The active character of bone’s turnover and aortic valve calcification can not regard CAS as degenerative, but regenerative process. The article is illustrated by case history, and elucidates the possibilities of pharmacological intervention, including new bisphosphonate drug – xydiphone.
About the Authors
N. Yu. Karpova
Russian State Medical University, Ministry of Health and Social Development of Russia
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
M. A. Rashyd
City Clinical Hospital № 55, Moscow
Russian Federation
Russian Federation
N. A. Shostak
Russian State Medical University, Ministry of Health and Social Development of Russia
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
T. V. Kazakova
Russian State Medical University, Ministry of Health and Social Development of Russia
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
Russian Federation
Acad. A.I. Nesterov’s Therapy Department
References
1. Mookadam F., Jalal U., Wilansky S. Aortic valve disease: preventable or inevitable? Future Cardiol 2010;6(6):777–83.
2. Nathaniel S., Saligram S., Innasimuthu A.L. Aortic stenosis: An update. World J Cardiol 2010;2(6):135–9.
3. Bunting C. The formation of the bone with cellular (red) marrow in a sclerotic aorta. J Exp Med 1906;8:365–76.
4. Demer L., Tintut Y. Mineral exploration: search for the mechanism of vascular calcification and beyond. Arterioscl Thromb Vasc Biol 2003;23:1739–43.
5. Mohler E.R. 3rd. Mechanisms of aortic valve calcification. Am J Cardiol 2004;94(11):1396–402;A6.
6. O’Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of “degenerative” valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523–32.
7. Yetkin E., Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009;135(1):4–13.
8. Freeman R.V., Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316–26.
9. Giachelli C. Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol
10. ;154(3):671–5.
11. Virchow R. Cellular Pathology: as based upon physiological and pathological histology. NY: Dover, 1971.
12. Feldman T., Glagov S., Carrol J.D. Restenosis following successful balloon valvuloplasty: bone formation in aortic valve leaflets. Cathet Cardiovasc Diagn 1993;29(1):1–7.
13. Риггс Б.Л., Мелтон Л.Д. Остеопороз. М.: Бином, 2000.
14. Christodoulou C., Cooper C. What is osteoporosis? Postgrad Med J 2003;79:133–8.
15. International Osteoporosis Foundation – Servier RESEARCH AWARD IN OSTEOPOROSIS. Endocrinology 2005;146(8):3517.
16. Brown J.P., Fortier M., Frame H., et al. Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Cancer 2006;28(2 Suppl 1): 95–112.
17. Blume S.W, Curtis J.R. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int 2010, Dec 17 [Epub ahead of print]. PMID: 21165602.
18. Cooper C., Walker-Bone K., Arden N., Dennison E. Novel insights into the pathogenesis of osteoporosis: the role of intrauterine programming. Rheumatology (Oxford) 2000;39:1312–5.
19. Johnston C.C. Jr., Bjarnason N.H., Cohen F.J., et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year
20. data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med2000;160:3444–50.
21. von der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273–8.
22. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.JСlin Endocrinol Metab2001;86:631–7.
23. Kado D.M., Browner W.S., Blackwell T., et al. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 2000;15:1974–80.
24. Schulz E., Arfai K., Liu X., et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246–53.
25. Рашид М.А., Шостак Н.А., Казакова Т.В., Карпова Н.Ю. Кальцинированный аортальный стеноз: костный метаболизм и кальцификация аортального клапана у пожилых. Кардиология и сердечно-
26. сосудистая хирургия 2008;1(3):65–9.
27. Bone markers: biochemical and clinical perspectives. Eastell R., Bauman M., Hoyle N.R., et al., eds. London: Martin Dunitz Ltd., 2001.
28. Sherman S., Hollis B., Tobin J. Vitamin D status and related parameters in a healthy population: the effects of age, sex and season. J Clin Endocrinol Metab 1990;71:405–13.
29. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22(4):477–501.
30. van Doorn L., Lips P., Netelenbos J.C., Hackeng W.H. Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH(1–84)) in patients with primary hyperparathyroidism. Bone Miner 1993;23:233–42.
31. Krege J.H., Donley D.W., Marcus R. Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med 2005;353:634–5.
32. Barone A., Giusti A., Pioli G., et al. Secondary hyperparathyroidism due to hypovitaminosis d affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized
33. controlled trial. J Am Geriatr Soc 2007;55(5):752–7.
34. Meyer H.E., Henriksen C., Falch J.A., et al. Risk factors for hip fracture in a high incidence area: a case-control study from Oslo, Norway. Osteoporos Int 1995;5:239–46.
35. Melton L.J., Chrischilles E.A., Cooper C., et al. Perspective. How may women have osteoporosis? J Bone Miner Res 1992;7:1005–10.
36. Cashman K.D. Vitamin D in childhood and adolescence. Postgrad Med J 2007;83(978):230–5.
37. Graafmans W.C., Ooms M.E., Hofstee H.M., et al. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol 1996;143:1129–36.
38. Potts J.T. Parathyroid hormone: past and present. J Endocrinol 2005;187:311–25.
39. Ledger G.A., Burritt M.F., Kao P.C., et al. Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-(OH)2D. J Clin Endocrinol Metab 1994;79:211–6.
40. Minisola S., Pacitti M., Scarda A., et al. Serum ionized calcium, parathyroid hormone and related variables: effect of age and sex. Bone Miner 1993;23:183–93.
41. Holick M.F. The parathyroid hormone D-lema. J Clin Endocrinol Metab 2003;88(8):3499–500.
42. Need A.G., O’Loughlin P.D., Morris H.A., et al. The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center. J Clin
43. Endocrinol Metab 2004;89:1646–9.
44. Godman W.G., Salusky I.B., Juppner H. New lessons from old assays: PTH, its receptors and the potential biological relevance of PTH fragments. Nephrol Dial Transplant 2002;17:1731–6.
45. Hagström E., Hellman P., Larsson T.E., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:2765–71.
46. Sambrook P.N., Chen J.S., March L.M., et al. Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 2004;89:1572–6.
47. Bagger Y.Z., Rasmussen H.B., Alexandersen P., et al. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int
48. ;18(4):505–12.
49. Farhat G.N., Newman A.B., Sutton-Tyrrell K., et al., for the Health ABC study. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int 2007;18(7):999–1008.
50. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005;98:467–84.
51. Périard D., Folly A., Meyer M.A., et al. Aortic calcification and the risk of osteoporotic fractures (in French). Rev Med Suisse 2010;6(271):2200–3.
52. Kong Y.Y., Boyle W.J., Penninger J.M. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000;21:495–502.
53. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610–6.
54. Schoppet M., Preissner K., Hoftbauer L. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549–53.
55. Liu Y., Dvornyk V., Lu Y., et al. A novel pathophysiological mechanism for osteoporosis suggested by an in vivo Gene Expression Study of Circulating Monocytes. J Biol Chem 2005;280:2911–6.
56. Ghaisas N.K., Foley J.B., O’Briain D.S., et al. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000;36:2257–62.
57. Jian B., Jones P.L., Li Q., et al. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001;159:321–7.
58. Карпова Н.Ю., Шостак Н.А., Казакова Т.В., Рашид М.А. Кальцификация аортального клапана и состояние костного обмена у лиц пожилого возраста. Кардиология 2006;46(7):70–2.
59. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Под ред. Л.И. Беневоленской и О.М. Лесняк. М.: ГЭОТАР-Медиа, 2006.
60. Nieves J. Osteoporosis: the role of micronutrients. Am J Clin Nutrit 2005;81:1232–9.
61. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005;353:595–603.
62. Wagman R.B., Marcus R. Editorial: beyond bone mineral density – navigating the laboratory assessment of patients with osteoporosis. J Clin Endocrinol Metab 2002;87(10):4429–30.
63. Carabello B.A. Is it too late to operate on the patient with valvular heart disease. J Am Coll Cardiol 2004;2(44):376–83.
64. Otto C.M. Calcific aortic valve disease: outflow obstruction is the end stage of a systemic disease process. Eur Heart J 2009;30(16):1940–2.
65. Шостак Н.А., Карпова Н.Ю., Рашид М.А., Казакова Т.В. Кальцинированный аортальный стеноз и остеопороз: показатели костного метаболизма и системного обмена кальция у пожилых лиц. Терапевтический архив 2007;79(9):45–9.
66. Скрипникова И.А. Эффективность Бивалоса (стронция ранелата) в снижении риска остеопоротических переломов у женщин постменопаузального периода. Научно-практическая ревматология 2006;(2):31–6.
67. Ammann P., Badoud I., Barraud S., et al. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007;22(9):1419–25.
68. Canalis E. New treatment modalities in osteoporosis. Endocr Pract 2010;16(5):855–63.
69. Шварц Г.Я. Фармакотерапия остеопороза (лекарственные средства для лечения и профилактики). М.: МИА, 2002.
70. Валеева И.Х., Зиганшина Л.Е., Бурнашова З.А., Зиганшин А.У. Влияние димефосфона и ксидифона на минеральный обмен и перекисное окисление липидов крыс на модели «пульс-терапии»
71. преднизолоном. Экспериментальная и клиническая фармакология 2003;66(1):46–9.
72. Родионова С.С., Соловов В.Д., Дорохов В.В., Банаков В.В. Сравнительная оценка минеральной плотности костной ткани у ликвидаторов последствий аварии на ЧАЭС методом ультразвуковой денситометрии. Настоящее и будущее костной патологии. М., 1997.
73. Ершова А.К. О применении препарата ксидифон при нарушении кальциевого обмена. Русский медицинский журнал 2010;18(14):884–6.
74. Моисеев C.B. Антирезорбтивные средства и остеопоротические переломы. Клиническая фармакология и терапия 2004;(11):5–7.
Review
For citations:
Karpova N.Yu., Rashyd M.A., Shostak N.A., Kazakova T.V. CALCIFIC AORTIC STENOSIS AND OSTEOPOROSIS: GENERAL MECHANISMS AND PERSPECTIVES OF PHARMACOLOGICAL CORRECTION. The Clinician. 2011;5(2):86-93. (In Russ.) https://doi.org/10.17650/1818-8338-2011-2-86-93
Views:
964
Email this article 